Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Subviral Agents01:29

Subviral Agents

567
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
567
Group Therapy01:26

Group Therapy

446
Group therapy is a sociocultural approach to psychological treatment, where individuals with shared psychological challenges come together under the guidance of a mental health professional. This therapeutic modality offers unique opportunities for individuals to connect, share, and grow within the context of a supportive group. By fostering mutual understanding and collaboration, group therapy can address a range of psychological concerns effectively, often complementing or surpassing the...
446
Air-entraining Agents01:27

Air-entraining Agents

273
Air-entraining agents improve the durability and workability of concrete in climates with frequent freezing and thawing. These agents prevent cracks by introducing small air bubbles into the mix, creating spaces accommodating water expansion when temperatures drop. The air-entraining agents lower the surface tension of water, forming stable, small air bubbles. This method is more effective than having accidental large voids, as the intentional, smaller, and evenly distributed air voids improve...
273
Cancer Therapies02:49

Cancer Therapies

10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Behavior Therapy01:22

Behavior Therapy

713
Behavior therapy incorporates diverse techniques rooted in classical conditioning principles to address maladaptive behaviors and anxiety disorders. These methods aim to reduce avoidance behaviors, foster adaptive coping mechanisms, and alter associations between stimuli and responses, making them effective in a wide range of therapeutic contexts.
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
713

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

American journal of hematology·2026
Same author

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Blood advances·2026
Same author

Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia.

Advances in therapy·2026
Same author

Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML.

bioRxiv : the preprint server for biology·2025
Same author

Balancing Activation and Repression: CoREST-p300 Antagonism Controls Retinoic Acid-Driven Differentiation in AML.

bioRxiv : the preprint server for biology·2025
Same author

<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.

Haematologica·2025

Related Experiment Video

Updated: Feb 4, 2026

An Alternative Culture Method to Maintain Genomic Hypomethylation of Mouse Embryonic Stem Cells Using MEK Inhibitor PD0325901 and Vitamin C
11:53

An Alternative Culture Method to Maintain Genomic Hypomethylation of Mouse Embryonic Stem Cells Using MEK Inhibitor PD0325901 and Vitamin C

Published on: June 1, 2018

7.1K

Leveraging Hypomethylating Agents for Better MDS Therapy.

Terrence J Bradley1, Justin M Watts2, Ronan T Swords2

  • 1Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 90 SW 3rd Street #2210, Miami, FL, 33130, USA. Tjb127@med.miami.edu.

Current Hematologic Malignancy Reports
|September 30, 2018
PubMed
Summary

New therapies combining hypomethylating agents with novel treatments show promise for myelodysplastic syndrome (MDS) patients, improving response rates and potentially altering standard care for this heterogeneous blood cancer.

Keywords:
Acute myeloid leukemiaHypomethylating agentsImmunotherapyIsocitrate dehydrogenaseMyelodysplastic syndromePevonedistat

More Related Videos

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
11:27

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging

Published on: December 4, 2016

10.6K
Leveraging Micro-CT Scanning to Analyze Parasitic Plant-Host Interactions
06:23

Leveraging Micro-CT Scanning to Analyze Parasitic Plant-Host Interactions

Published on: January 12, 2022

2.4K

Related Experiment Videos

Last Updated: Feb 4, 2026

An Alternative Culture Method to Maintain Genomic Hypomethylation of Mouse Embryonic Stem Cells Using MEK Inhibitor PD0325901 and Vitamin C
11:53

An Alternative Culture Method to Maintain Genomic Hypomethylation of Mouse Embryonic Stem Cells Using MEK Inhibitor PD0325901 and Vitamin C

Published on: June 1, 2018

7.1K
Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
11:27

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging

Published on: December 4, 2016

10.6K
Leveraging Micro-CT Scanning to Analyze Parasitic Plant-Host Interactions
06:23

Leveraging Micro-CT Scanning to Analyze Parasitic Plant-Host Interactions

Published on: January 12, 2022

2.4K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Myelodysplastic syndrome (MDS) is a heterogeneous blood disorder primarily affecting older adults.
  • Current standard treatments, hypomethylating agents, offer survival benefits but lack durable responses for many patients.
  • Allogeneic stem cell transplant remains the only curative option for MDS, highlighting the need for novel therapies.

Purpose of the Study:

  • To review recent findings on novel therapeutic strategies for myelodysplastic syndrome (MDS).
  • To evaluate the potential of combination therapies in improving clinical outcomes for MDS patients.
  • To identify emerging treatments that may change the standard of care for MDS.

Main Methods:

  • Review of ongoing clinical trials combining hypomethylating agents with novel experimental agents.
  • Analysis of data on small molecules designed to augment hypomethylating agent efficacy.
  • Evaluation of combination approaches in both front-line and refractory MDS settings.

Main Results:

  • Several novel small molecules have shown potential to increase response rates to hypomethylating agents.
  • Combination therapies have demonstrated improved complete remission rates in MDS patients.
  • These novel combinations show promise in both initial treatment and salvage settings.

Conclusions:

  • Combination therapies involving hypomethylating agents and novel targeted agents are a promising avenue for improving MDS treatment outcomes.
  • These novel approaches may lead to enhanced response rates and more durable remissions in MDS patients.
  • Emerging combination strategies have the potential to significantly alter the current standard of care for myelodysplastic syndrome.